228 related articles for article (PubMed ID: 9209954)
1. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
[TBL] [Abstract][Full Text] [Related]
2. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
[TBL] [Abstract][Full Text] [Related]
3. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
4. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
5. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
[TBL] [Abstract][Full Text] [Related]
6. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
7. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.
van Es JM; Polak MM; van den Berg FM; Ramsoekh TB; Craanen ME; Hruban RH; Offerhaus GJ
J Clin Pathol; 1995 Mar; 48(3):218-22. PubMed ID: 7730480
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
12. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma.
Visscher DW; Yadrandji S; Tabaczka P; Kraut M; Sarkar FH
Diagn Mol Pathol; 1997 Feb; 6(1):64-9. PubMed ID: 9028739
[TBL] [Abstract][Full Text] [Related]
14. Patterns of genetic alterations in pancreatic cancer: a pooled analysis.
Blanck HM; Tolbert PE; Hoppin JA
Environ Mol Mutagen; 1999; 33(2):111-22. PubMed ID: 10217065
[TBL] [Abstract][Full Text] [Related]
15. K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines.
Suwa H; Yoshimura T; Yamaguchi N; Kanehira K; Manabe T; Imamura M; Hiai H; Fukumoto M
Jpn J Cancer Res; 1994 Oct; 85(10):1005-14. PubMed ID: 7961102
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
17. Structural alteration of p53 protein correlated to survival in patients with pancreatic adenocarcinoma.
Li Y; Bhuiyan M; Vaitkevicius VK; Sarkar FH
Pancreas; 1999 Jan; 18(1):104-10. PubMed ID: 9888666
[TBL] [Abstract][Full Text] [Related]
18. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas.
Lu L; Zeng J
PLoS One; 2017; 12(7):e0181532. PubMed ID: 28742845
[TBL] [Abstract][Full Text] [Related]
20. Novel method for simultaneous analysis of p53 and K-ras mutations and p53 protein expression in single histologic sections.
Yamashita K; Yoshida T; Shinoda H; Okayasu I
Arch Pathol Lab Med; 2001 Mar; 125(3):347-52. PubMed ID: 11231481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]